| pubmed-article:17644319 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17644319 | lifeskim:mentions | umls-concept:C0033809 | lld:lifeskim |
| pubmed-article:17644319 | lifeskim:mentions | umls-concept:C0205360 | lld:lifeskim |
| pubmed-article:17644319 | lifeskim:mentions | umls-concept:C0164503 | lld:lifeskim |
| pubmed-article:17644319 | lifeskim:mentions | umls-concept:C1956756 | lld:lifeskim |
| pubmed-article:17644319 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:17644319 | pubmed:dateCreated | 2007-10-8 | lld:pubmed |
| pubmed-article:17644319 | pubmed:abstractText | FR264205 is a novel parenteral 3'-aminopyrazolium cephalosporin. Here, we compared the stability of FR264205 against AmpC beta-lactamase of Pseudomonas aeruginosa with that of ceftazidime. The effect of ampD inactivation, which causes a moderate degree of hyperinducible AmpC expression, on the minimum inhibitory concentration (MIC) of FR264205 was eight-fold less than that on the MIC of ceftazidime. Hydrolysis efficiency (k(cat)/K(m)) towards FR264205 was substantially lower than that towards ceftazidime owing to a 20-fold-higher K(m) value. These results indicate that FR264205 is more stable against AmpC beta-lactamase than ceftazidime because of its low affinity. | lld:pubmed |
| pubmed-article:17644319 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17644319 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17644319 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17644319 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17644319 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17644319 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17644319 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17644319 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17644319 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17644319 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17644319 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17644319 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17644319 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:17644319 | pubmed:issn | 0924-8579 | lld:pubmed |
| pubmed-article:17644319 | pubmed:author | pubmed-author:YamaguchiKeiz... | lld:pubmed |
| pubmed-article:17644319 | pubmed:author | pubmed-author:TatedaKazuhir... | lld:pubmed |
| pubmed-article:17644319 | pubmed:author | pubmed-author:IshiiYoshikaz... | lld:pubmed |
| pubmed-article:17644319 | pubmed:author | pubmed-author:HatanoKazuoK | lld:pubmed |
| pubmed-article:17644319 | pubmed:author | pubmed-author:TakedaShinobu... | lld:pubmed |
| pubmed-article:17644319 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17644319 | pubmed:volume | 30 | lld:pubmed |
| pubmed-article:17644319 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17644319 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17644319 | pubmed:pagination | 443-5 | lld:pubmed |
| pubmed-article:17644319 | pubmed:meshHeading | pubmed-meshheading:17644319... | lld:pubmed |
| pubmed-article:17644319 | pubmed:meshHeading | pubmed-meshheading:17644319... | lld:pubmed |
| pubmed-article:17644319 | pubmed:meshHeading | pubmed-meshheading:17644319... | lld:pubmed |
| pubmed-article:17644319 | pubmed:meshHeading | pubmed-meshheading:17644319... | lld:pubmed |
| pubmed-article:17644319 | pubmed:meshHeading | pubmed-meshheading:17644319... | lld:pubmed |
| pubmed-article:17644319 | pubmed:meshHeading | pubmed-meshheading:17644319... | lld:pubmed |
| pubmed-article:17644319 | pubmed:meshHeading | pubmed-meshheading:17644319... | lld:pubmed |
| pubmed-article:17644319 | pubmed:meshHeading | pubmed-meshheading:17644319... | lld:pubmed |
| pubmed-article:17644319 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17644319 | pubmed:articleTitle | Stability of FR264205 against AmpC beta-lactamase of Pseudomonas aeruginosa. | lld:pubmed |
| pubmed-article:17644319 | pubmed:affiliation | Pharmacology Research Laboratories, Astellas Pharma Inc., 1-6, Kashima 2-chome, Yodogawa-ku, Osaka 532-8514, Japan. shinobu.takeda@jp.astellas.com | lld:pubmed |
| pubmed-article:17644319 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17644319 | pubmed:publicationType | Comparative Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17644319 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17644319 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17644319 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17644319 | lld:pubmed |
